Scientists use PBMC from HemaCare for experiments that show the potential of a new cancer vaccine adjuvant. T cells answer the alarm!
Researchers explore a new, less expensive option for manufacturing dendritic cells as cancer vaccines. HemaCare helped make it possible.
Precision medicine has become quite the catchphrase. In essence, it is an approach towards embracing medical therapy that is precise for the individual. One strategy relies on the patient’s genome. This entails pinpointing DNA mutations and proteins on patient biopsy samples using molecular diagnostics, as the same disease can have diverse causes in different patients. Such knowledge then leads to targeted therapy effective at the molecular level.
Stem cells are lost in the fog of other cells once administered into the body. With MRI and fluorine-19 labeling, we could track their trek.
We could be headed towards developing cancer vaccines using genomic and proteomic information from PBMC.